

bcl172
bcl180
bcl200
HIV-1 pol476
Binding (arbitrary units)
120
100
80
60
40
20
0
50
5
0,5
0,05
Peptide conc. (mikroM)

Fig. 1



Peptide specific cells/10e5
200
180
160
140
120
100
80
60
40
20
0
-20
1
9
10
11
12
13
14
15
16
17
19
20
21
22
2
Breast cancer patients
Bcl2_172
Bcl2_180
Bcl2_208
Bcl2_214

Fig. 2



A
bcl208
B
bcl214
Peptide specific cells/10^5
140
120
100
80
60
40
20
0
-20
CLL
AML
Pancreatic cancer

Fig. 3



A
B
bcl208
bcl214
Peptide specific, GrB releasing cells/10e5
140
120
100
80
60
40
20
0
b19 b20 b22 b16 h1

Fig. 4



A
35
25
15
5
-5
Lysis (%)
T2
T2/bcl208
10:1
3:1
1:1
E:T ratio
B
55
45
35
25
15
5
-5
Lysis (%)
MDA-MB-231
ZR75-1
30:1
10:1
3:1
1:1
E:T ratio

Fig. 5



A
BclX(L)173-182 specific cells/3x10e5
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-20
healthy
BC patients
Melanoma
PC patients
B
BclX(L)141-150 specific cells/3x10e5
C
BclX(L)161-170 specific cells/3x10e5
D
BclX(L)165-174 specific cells/3x10e5

Fig. 6



Bcl-X(L)173-182 specific, GrB releasing cells/3x10e5
100
90
80
70
60
50
40
30
20
10
0
BC35
BC36
BC17

Fig. 7



A
BC36-BCL-X173
CD8
BCL-x173
CD8 APC-A
Pentamer PE-A
B
BC36-HIV A2
CD8
HIV
CD8 APC-A
Pentamer PE-A
C
spots per 4,5X10 4 CD8 T cells
800
700
600
500
400
300
200
100
0
BC36
No peptide
BCL-X 173

Fig. 8



A
B
BclX specific cells/3x10e5
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-20
Breast cancer
Pancreatic cancer
Melanoma

Fig. 9



BclX specific cells/10e5
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-20
healthy individuals
Breast cancer
Melanoma
Pancreas cancer
Multiple Myeloma

Fig. 10



Mcl-1(95-103)
Mcl-1(95-103) specific cells/3x10e5
340
320
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-20
Healthy
BC patients
PC patients
CLL patients
Mcl-1(300-309)
Mcl-1(300-308) specific cells/3x10e5
340
320
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-20
Healthy
BC patients
PC patients
CLL patients

Fig. 11



Mcl-1(177-185) specific cells/5x10e5
340
320
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-20
Healthy
BC patients
melanoma
Mcl-1(166-175) specific cells/3x10e5
340
320
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-20
Healthy
BC patients
melanoma

Fig. 12

SEQUENCE LISTING

<110> Kræftens Bekæmpelse

<120> Proteins belonging to the Bcl-2 family and fragments thereof and their use in cancer patients

<130> P 985 PC00

<160> 64

<170> PatentIn version 3.1

<210> 1
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 1

Ala Leu Val Gly Ala Cys Ile Thr Leu
1 5

<210> 2
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 2

Ala Leu Ser Pro Val Pro Pro Val Val
1 5

<210> 3
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 3

Ser Leu Ala Leu Val Gly Ala Cys Ile
1 5

<210> 4
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 4

Lys Thr Leu Leu Ser Leu Ala Leu Val
1 5

<210> 5
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 5

Leu Leu Ser Leu Ala Leu Val Gly Ala
1 5

<210> 6
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 6

Trp Leu Ser Leu Lys Thr Leu Leu Ser Leu
1 5 10

<210> 7
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 7

Ala Ala Ala Gly Pro Ala Leu Ser Pro Val
1 5 10

<210> 8
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 8

Pro Leu Phe Asp Phe Ser Trp Leu Ser Leu
1 5 10

<210> 9
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 9

Phe Thr Ala Arg Gly Arg Phe Ala Thr Val
1 5 10

<210> 10
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 10

Tyr Leu Asn Arg His Leu His Thr Trp Ile
1 5 10

<210> 11
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 11

Asn Ile Ala Leu Trp Met Thr Glu Tyr Leu
1 5 10

<210> 12
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Survivin

<400> 12

Phe Leu Lys Leu Asp Arg Glu Arg Ala
1 5

<210> 13
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Survivin

<400> 13

Thr Leu Pro Pro Ala Trp Gln Pro Phe Leu
1 5 10

<210> 14
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Survivin

<400> 14

Glu Leu Thr Leu Gly Glu Phe Leu Lys Leu
1 5 10

<210> 15
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Modified survivin derived peptide

<400> 15

Leu Leu Leu Gly Glu Phe Leu Lys Leu
1 5

<210> 16
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Modified survivin derived peptide

<400> 16

Leu Met Leu Gly Glu Phe Leu Lys Leu
1 5

<210> 17
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Survivin

<400> 17

Cys Pro Thr Glu Asn Glu Pro Asp Leu
1 5

<210> 18
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Survivin

<400> 18

Glu Pro Asp Leu Ala Gln Cys Phe Phe
1 5

<210> 19
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Modified survivin derived peptide

<400> 19

Cys Pro Thr Glu Asn Glu Pro Asp Tyr
1 5

<210> 20
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Modified survivin derived peptide

<400> 20

Glu Pro Asp Leu Ala Gln Cys Phe Tyr
1 5

<210> 21
<211> 9

<212> PRT
<213> artificial sequence

<220>
<223> Modified survivin derived peptide

<400> 21

Met Ala Glu Ala Gly Phe Ile His Tyr
1 5

<210> 22
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Modified survivin derived peptide

<400> 22

Pro Thr Glu Asn Glu Pro Asp Leu Ala Tyr
1 5 10

<210> 23
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Survivin

<400> 23

Gln Phe Glu Glu Leu Thr Leu Gly Glu Phe
1 5 10

<210> 24
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Modified survivin derived peptide

<400> 24

Phe Thr Glu Leu Thr Leu Gly Glu Phe
1 5

<210> 25
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Modified survivin derived peptide

<400> 25

Arg Ile Ser Thr Phe Lys Asn Trp Pro Lys
1 5 10

<210> 26
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Survivin

<400> 26

Asp Leu Ala Gln Cys Phe Phe Cys Phe Lys
1 5 10

<210> 27
<211> 11
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Survivin

<400> 27

Arg Ile Ser Thr Phe Lys Asn Trp Pro Phe Leu
1 5 10

<210> 28
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 28

Arg Leu Gln Glu Glu Arg Thr Cys Lys Val
1 5 10

<210> 29
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 29

Gln Leu Cys Pro Ile Cys Arg Ala Pro Val
1 5 10

<210> 30
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 30

Arg Leu Ala Ser Phe Tyr Asp Trp Pro Leu
1 5 10

<210> 31
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 31

Leu Leu Arg Ser Lys Gly Arg Asp Phe Val
1 5 10

<210> 32
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 32

Val Leu Glu Pro Pro Gly Ala Arg Asp Val
1 5 10

<210> 33
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 33

Pro Leu Thr Ala Glu Val Pro Pro Glu Leu

1 5 10

<210> 34
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 34

Ser Leu Gly Ser Pro Val Leu Gly Leu
1 5

<210> 35
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 35

Gln Ile Leu Gly Gln Leu Arg Pro Leu
1 5

<210> 36
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 36

Leu Thr Ala Glu Val Pro Pro Glu Leu
1 5

<210> 37
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 37

Gly Met Gly Ser Glu Glu Leu Arg Leu
1 5

<210> 38
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from ML-IAP

<400> 38

Glu Leu Pro Thr Pro Arg Arg Glu Val
1 5

<210> 39
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Epitope from HIV-1 pol

<400> 39

Ile Leu Lys Glu Pro Val His Gly Val
1 5

<210> 40
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 40

Ser Leu Lys Thr Leu Leu Ser Leu Ala Leu
1 5 10

<210> 41
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-2

<400> 41

Glu Leu Tyr Gly Pro Ser Met Arg Pro Leu
1 5 10

<210> 42
<211> 10
<212> PRT

<213> artificial sequence

<220>
<223> Peptide derived from Bcl-XL

<400> 42

Tyr Leu Asn Asp His Leu Glu Pro Trp Ile
1 5 10

<210> 43
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-XL

<400> 43

Thr Ala Tyr Gln Ser Phe Glu Gln Val
1 5

<210> 44
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-XL

<400> 44

Glu Met Gln Val Leu Val Ser Arg Ile
1 5

<210> 45
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-XL

<400> 45

Arg Ile Ala Ala Trp Met Ala Thr Tyr Leu
1 5 10

<210> 46
<211> 10
<212> PRT
<213> artificial sequence

<220>

<223> Peptide derived from Bcl-XL

<400> 46

Trp Met Ala Thr Tyr Leu Asn Asp His Leu
1 5 10

<210> 47
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Modified Bcl-2 peptide

<400> 47

Pro Leu Phe Asp Phe Ser Trp Val Ser Leu
1 5 10

<210> 48
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-XL

<400> 48

Val Leu Val Ser Arg Ile Ala Ala Trp Met
1 5 10

<210> 49
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-XL

<400> 49

Val Ala Phe Phe Ser Phe Gly Gly Ala Leu
1 5 10

<210> 50
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-XL

<400> 50

Arg Ile Ala Ala Trp Met Ala Thr Tyr
1 5

<210> 51
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Bcl-XL

<400> 51

Ala Leu Cys Val Glu Ser Val Asp Lys
1 5

<210> 52
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 52

Tyr Leu Arg Glu Gln Ala Thr Gly Ala Lys
1 5 10

<210> 53
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 53

Ser Ile Thr Asp Val Leu Val Arg Thr Lys
1 5 10

<210> 54
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 54

Leu Ile Ser Phe Gly Ala Phe Val Ala Lys
1 5 10

<210> 55
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 55

Arg Leu Leu Phe Phe Ala Pro Thr Arg
1 5

<210> 56
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 56

Arg Thr Lys Arg Asp Trp Leu Val Lys
1 5

<210> 57
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 57

Asp Ile Lys Asn Glu Asp Asp Val Lys
1 5

<210> 58
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 58

Pro Ala Glu Glu Glu Glu Asp Asp Leu Tyr
1 5 10

<210> 59

<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 59

Ser Pro Glu Glu Glu Leu Asp Gly Tyr
1 5

<210> 60
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 60

Gln Ser Leu Glu Ile Ile Ser Arg Tyr
1 5

<210> 61
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Peptide derived from Mcl-1

<400> 61

Ala Gly Val Gly Ala Gly Leu Ala Tyr
1 5

<210> 62
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Modified Mcl-1 peptide

<400> 62

Arg Leu Lys Arg Asp Trp Leu Val Lys
1 5

<210> 63
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Modified Mcl-1 peptide

<400> 63

Gln Ser Asp Glu Ile Ile Ser Arg Tyr
1 5

<210> 64
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> Modified Mcl-1 peptide

<400> 64

Gln Ser Glu Glu Ile Ile Ser Arg Tyr
1 5